Abivax S.A.

End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView

Company profile

We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. We were incorporated as a société anonyme (limited liability company) on December 4, 2013 and registered at the Paris Trade and Company Register on December 27, 2013 for a period of 99 years until December 22, 2112, subject to extension or early dissolution, under the number 799 363 718. Our principal executive offices are located at 7-11 boulevard Haussmann 75009 Paris, France, and our telephone number is +33 (0) 1 53 83 08 41. We have one wholly owned subsidiary, Abivax LLC, a Delaware limited liability company, formed on March 20, 2023. Our agent for service of process in the United States is CT Corporation System, 1015 15th Street N.W., Suite 1000, Washington, D.C.

CEO

Marc de Garidel

Sector

Manufacturing

Industry

Pharmaceutical Products

Website

www.abivax.com

Consensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.

No insider transactions in the last 12 months.